Medtronic PLC $MDT Shares Acquired by Principal Financial Group Inc.

Principal Financial Group Inc. grew its stake in Medtronic PLC (NYSE:MDT - Free Report) by 3.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,720,207 shares of the medical technology company's stock after acquiring an additional 64,052 shares during the quarter. Principal Financial Group Inc. owned about 0.13% of Medtronic worth $165,243,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Medtronic by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company's stock worth $12,388,027,000 after acquiring an additional 1,888,381 shares during the last quarter. State Street Corp increased its stake in shares of Medtronic by 1.0% in the 3rd quarter. State Street Corp now owns 60,460,537 shares of the medical technology company's stock worth $5,800,550,000 after acquiring an additional 625,992 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Medtronic by 0.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company's stock worth $2,044,637,000 after purchasing an additional 192,410 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in shares of Medtronic by 0.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company's stock worth $2,008,278,000 after purchasing an additional 98,220 shares during the period. Finally, Raymond James Financial Inc. grew its holdings in shares of Medtronic by 3.0% during the 3rd quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company's stock worth $1,067,055,000 after purchasing an additional 327,899 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MDT has been the subject of a number of research analyst reports. Daiwa Securities Group lowered their price target on Medtronic from $117.00 to $115.00 and set a "buy" rating for the company in a report on Friday, February 27th. Sanford C. Bernstein lifted their price target on shares of Medtronic from $111.00 to $112.00 and gave the company an "outperform" rating in a research report on Friday, January 9th. Evercore set a $106.00 price objective on shares of Medtronic and gave the stock an "outperform" rating in a report on Thursday, April 9th. CICC Research initiated coverage on shares of Medtronic in a report on Friday, January 30th. They issued an "outperform" rating on the stock. Finally, Argus decreased their price objective on shares of Medtronic from $125.00 to $115.00 and set a "buy" rating on the stock in a report on Monday, April 6th. Fifteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $107.80.

Medtronic Stock Performance

NYSE MDT opened at $77.77 on Wednesday. The company has a market cap of $99.85 billion, a P/E ratio of 21.66, a P/E/G ratio of 1.86 and a beta of 0.62. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The stock has a 50-day moving average of $88.06 and a two-hundred day moving average of $94.68. Medtronic PLC has a 1-year low of $77.39 and a 1-year high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic's revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts anticipate that Medtronic PLC will post 5.57 EPS for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.7%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic's payout ratio is currently 79.11%.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic won a CE mark for its VitalFlow ECMO transport technology, expanding its critical-care portfolio in markets that accept CE certification — a direct commercial upside for its acute-care product lineup. Medtronic wins CE mark for VitalFlow ECMO transport tech
• Positive Sentiment: Medtronic emphasized momentum for the Affera cardiac arrhythmia franchise and noted a Breakthrough Device designation from FDA for related tech — this can accelerate trials, regulatory review and adoption, supporting medium-term growth in electrophysiology. Medtronic (MDT) Highlights Affera Momentum and FDA Breakthrough Device Designation
• Neutral Sentiment: Some analysts are recalibrating Medtronic’s fair value modestly (example: a trim from ~$109.08 to ~$108.00) and offering mixed views — this reflects divergence on how to value guidance and the pipeline rather than a consensus sell signal. How The Medtronic (MDT) Story Is Shifting As Guidance Meets Mixed Wall Street Views
• Neutral Sentiment: Competitive dynamics in diabetes devices continue to attract attention (analyst pieces on Dexcom and CGM market growth). A stronger CGM competitor landscape is a mixed influence: it validates market expansion but may pressure Medtronic’s share in certain segments. 3 Reasons Analysts Love DexCom (MDT)
• Negative Sentiment: Short-term selling pressure and session-to-session declines have shown up in market reports — coverage noting multi-percent drops over recent sessions is contributing to negative momentum and added volatility. Medtronic (MDT) Stock Sinks As Market Gains: Here's Why

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares of the company's stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.